The independent source for health policy research, polling, and news.
1 - 20 of 695 Results
Margaret Hvatum ended up in the hospital after her insurer denied coverage of a medicine she relies on to boost her immune system. Hvatum got entangled in the preapproval process, which the insurance industry has vowed to improve.
If your doctor prescribes a GLP-1 medication for weight loss but your insurance won’t cover it, you have options.
Many telehealth companies have emerged in recent years offering easy access to GLP-1 weight loss drugs as demand has exploded. Meanwhile, researchers and doctors are concerned that some of these online companies aren't properly screening or monitoring patients. “It gives a black eye to telemedicine,” one researcher said.
Get our weekly newsletter, The Week in Brief, featuring a roundup of our original coverage, Fridays at 2 p.m. ET.
KFF Health News journalists made the rounds on national media recently to discuss topical stories. Here’s a collection of their appearances.
The new TrumpRx program relies partly on connecting consumers with discount coupons offered by drugmakers. For insured patients, though, using a coupon can prove dicey.
For all of President Donald Trump’s showmanship, the share of Americans his policies will likely help remains slim, even if some patients do come out ahead.
It may soon get easier for millions of people with Medicare to get discounted GLP-1 drugs for weight loss.
In “Hikma v. Amarin,” the Supreme Court’s decision could affect how quickly generic versions of brand-name medicines come to market.
This week, the Trump administration won a court battle to delay a ruling on access to the abortion pill mifepristone, angering its own anti-abortion allies. Meanwhile, the president’s budget arrived on Capitol Hill, where lawmakers are unlikely to agree to its proposed cuts to Health and Human Services programs. Lauren Weber of The Washington Post, Alice Miranda Ollstein of Politico, and Maya Goldman of Axios join KFF Health News’ Julie Rovner to discuss these stories and more.
It’s been a busy week at the FDA, with a political appointee overruling agency scientists to reject an application for a new flu vaccine. Meanwhile, anti-abortion Republicans on Capitol Hill complain the agency is dragging its feet on reviewing the abortion pill mifepristone. Jackie Fortiér of KFF Health News, Lizzy Lawrence of Stat, and Alice Miranda Ollstein of Politico join KFF Health News’ Julie Rovner to discuss these stories and more.
Lawmakers appear on the brink of passing a spending bill for the Department of Health and Human Services and a bipartisan health policy bill delayed for over a year. But the outlook is bleaker for the health care outline released by President Trump last week. Sandhya Raman of CQ Roll Call, Sheryl Gay Stolberg of The New York Times, and Paige Winfield Cunningham of The Washington Post join KFF Health News’ Julie Rovner to discuss those stories and more. Also this week, Rovner interviews oncologist and bioethicist Ezekiel Emanuel to discuss his new book, “Eat Your Ice Cream.”
The government is using sickle cell treatments to test a new strategy: paying only if the therapies benefit patients. With more expensive treatments on the horizon, the program — created by the Biden administration and continued under President Trump — could help Medicaid save money and treat more patients.
An estimated 4.8 million people are expected to go without health coverage because Congress did not extend enhanced subsidies for Affordable Care Act plans. But even without a health plan, people will need medical care in 2026. Many of them have been thinking through their plan B to maintain their health.
Low-income Californians who use Wegovy and similar medications for weight loss lost their coverage at the start of the new year, with officials advising diet and exercise instead. California and other states say the drugs are too costly, even as the Trump administration announces plans to lower prices.
In some studies, half of patients stopped taking GLP-1s within a year despite the benefits, citing the expense and side effects.
It’s been more than 10 years since the FDA first approved an HIV prevention drug. Today, people who could benefit from preexposure prophylaxis often struggle to access the lifesaving medicine or run into doctors without the education or empathy to offer affirming care. And those lapses can produce billing headaches.
Drug industry officials and analysts praised the FDA’s plans to streamline regulation of “biosimilars,” which are cheaper alternatives to biologic drugs. But patents that block such drugs from the U.S. market are getting harder to fight.
Democrats and Republicans remain stalled over funding the federal government as Republicans launch a new attack on the Affordable Care Act. Meanwhile, the Trump administration is taking advantage of the shutdown to lay off workers from programs supported mostly by Democrats. Anna Edney of Bloomberg News, Lauren Weber of The Washington Post, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico Magazine join KFF Health News’ Julie Rovner to discuss those stories and more. Also this week, Rovner interviews health insurance analyst Louise Norris about Medicare open enrollment.
In Mississippi, a state with one of the highest obesity rates in the nation, Medicaid covers weight loss drugs, but few enrollees have signed up for the benefit.
© 2026 KFF